SCHEMBL20173805

SCHEMBL20173805

CC(C)N1CCc2cc(C(=O)NCC(=O)O)ccc2C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.44
HDAC8 Q9BY41 1/20 0.44
PTGER1 P34995 1/20 0.43
PRMT5 O14744 5/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PTPRC P08575 2/20 0.42
CTSL P07711 1/20 0.42
PTPN13 Q12923 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
OPRK1 P41145 2/20 0.42
OPRM1 P35372 1/20 0.42
MAPT P10636 2/20 0.41
HSP90AA1 P07900 1/20 0.41
HIF1A Q16665 1/20 0.40
SLC22A6 Q4U2R8 1/20 0.40
SLC22A8 Q8TCC7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119170 0.84 USP5 (0.47) HDAC6HDAC8KDM4EMAPK1ALDH1A1
SCHEMBL21882599 0.83 HDAC6 (0.43) HDAC6HDAC8PTGER1PRMT5HTT
SCHEMBL25873240 0.82 POLB (0.50) HDAC6HDAC8PTGER1ALDH1A1HTT
SCHEMBL20173793 0.82 ALDH1A1 (0.51) HDAC6HDAC8PTGER1KDM4EALDH1A1
SCHEMBL20173806 0.81 OPRK1 (0.45) HDAC6HDAC8PTGER1PRMT5HTT
SCHEMBL3879495 0.78 ACACB (0.54) HDAC6HDAC8PTGER1KDM4EALDH1A1
SCHEMBL13791770 0.78 HDAC6 (0.42) HDAC6HDAC8PTGER1KDM4EALDH1A1
SCHEMBL26161462 0.78 HSD17B3 (0.51) HDAC6HDAC8PTGER1KDM4EALDH1A1
SCHEMBL26167813 0.78 PTGER1 (0.44) HDAC6HDAC8PTGER1KDM4EALDH1A1
SCHEMBL1787866 0.77 HRH3 (0.52) HDAC6HDAC8KDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 HDAC6 597/4885HDAC8 1166/4885PTGER1 681/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 HDAC6 597/4885HDAC8 1166/4885PTGER1 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.